Procures, manufactures, prepares, and sells therapeutic products, primarily hemoderivatives. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 11% a year over the last 4 years. Every year shown ended in profit.
The gap is $10.2B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 16.5× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 11% a year on average.
It pays out $0.09 per share each year — regular cash for whoever holds the stock.
Getting in and out without moving the price could prove difficult.
Since the drop from its peak, buyer appetite hasn’t come back.
Against everything we grade, GIFLF lands somewhere in the middle. The grade moves as the numbers move.
The takeaway: GIFLF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.